Previous 10 | Next 10 |
2023-10-25 10:49:08 ET More on AmWell, Teladoc, etc. Teladoc Health, Inc. (TDOC) Q3 2023 Earnings Call Transcript Teladoc Looks Ill As Amazon Threat Looms Teladoc: Broken Growth Story Deteriorates Further (Rating Downgrade) Biggest stock movers today: Snap, A...
2023-10-19 09:58:30 ET More on Sanofi, GoodRx, etc. GoodRx Faces Challenges In Subscription Plans, But Its Valuation Already Prices This In GoodRx Stock: Earnings Momentum Keeps It Interesting Sanofi: 3 Reasons For A Buy Sanofi presents encouraging data on at...
Integration allows people living with diabetes – with or without insurance – to access Sanofi’s most-prescribed insulin at a fixed rate anywhere GoodRx is accepted GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today an...
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, today announced it will release its third quarter 2023 financial results before U.S. markets open on Thursday, November 9, 2023. GoodRx manage...
Eligible Navitus members can now automatically access real-time comparative pricing at point of sale to improve affordability GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, and Navitus Health Solutions, LLC , a pass-through pharmacy benefit man...
2023-10-10 18:08:38 ET Gainers: VOXX International ( VOXX ) +10% . BioAtla ( BCAB ) +6% . Poseida Therapeutics ( PSTX ) +5% . Diversified Healthcare ( DHC ) +5% . Alignment Healthcare ( ALHC ) +4% . Losers: Si...
2023-09-27 09:53:22 ET Summary GoodRx's investment thesis is positive. The company's near-term prospects are promising. GoodRx is experiencing strong revenue growth rates. Investment Thesis GoodRx (GDRX) is a healthcare platform that seeks to provide consumers wi...
2023-09-26 18:07:47 ET Summary GoodRx is generating solid profitability with growth in monthly active consumers to its prescription drugs discount platform. Management expects stronger trends into the second half of the year. The stock has been under pressure since the last qu...
Company saved Americans more than $20 million on cold and flu treatments last season GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is offering new savings on antivirals, medications and vaccines for the upcoming cold and flu s...
2023-09-19 13:06:15 ET More on GoodRx Holdings GoodRx Holdings: Stay Cautious In FY23 Until Clear Signs Of Growth Inflection Appear TD Cowen upgrades GoodRx on game-changing PBM partnerships; stock soars Seeking Alpha's Quant Rating on GoodRx Holdings For fur...
News, Short Squeeze, Breakout and More Instantly...
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® PR Newswire First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and S...
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management ...
Former Genentech CEO brings over 35 years of pharmaceutical and healthcare expertise to GoodRx GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the ...